返回 Agenda
Beyond Cancer: Why Pharma is Moving to High Quality Real-World Data for Immunology and Other Chronic Diseases
Session Chair(s)
Richard Gliklich, MD
Founder
OM1, United States
Unlike cancer, there has been less focus on using real-world data (RWD) for autoimmune and other chronic conditions. This session explores the basics of what makes RWD high-quality and the uses for accelerating research and evaluating outcomes in these areas.
Learning Objective : Identify real-world data (RWD) utility in autoimmune conditions across research and development; Define data quality and what 'GCP' for RWD means; Apply data to personalize healthcare through artificial intelligence.
Speaker(s)
Industry Update
Xia Wang, PHD
AstraZeneca, United States
Director, Health Informatics, Data Science and AI
Industry Update
Christopher P Boone, PHD, MHA
Oracle, United States
Group Vice President, Research Services, Life Sciences
Industry Update
Gary Curhan, DRSC, MD
OM1, United States
Chief Medical Officer